MX2018002899A - Tratamiento de retinitis pigmentosa. - Google Patents

Tratamiento de retinitis pigmentosa.

Info

Publication number
MX2018002899A
MX2018002899A MX2018002899A MX2018002899A MX2018002899A MX 2018002899 A MX2018002899 A MX 2018002899A MX 2018002899 A MX2018002899 A MX 2018002899A MX 2018002899 A MX2018002899 A MX 2018002899A MX 2018002899 A MX2018002899 A MX 2018002899A
Authority
MX
Mexico
Prior art keywords
retinitis pigmentosa
treatment
rpgrorf15
nucleotide sequence
encoding
Prior art date
Application number
MX2018002899A
Other languages
English (en)
Inventor
Maclaren Robert
Fischer Dominik
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54362987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018002899(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2018002899A publication Critical patent/MX2018002899A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11014—Rhodopsin kinase (2.7.11.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Un polinucleótido que comprende una secuencia de nucleótidos que codifica la isoforma de regulador ORF15 de GTPasa de retinitis pigmentosa (RPGRORF15), en donde la secuencia de nucleótidos que codifica RPGRORF15 ha sido optimizada en codones para aumentar la fidelidad de replicación de la secuencia.
MX2018002899A 2015-09-10 2016-09-09 Tratamiento de retinitis pigmentosa. MX2018002899A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1516066.6A GB201516066D0 (en) 2015-09-10 2015-09-10 Treatment of retinitis pigmentosa
PCT/GB2016/052802 WO2017042584A1 (en) 2015-09-10 2016-09-09 Treatment of retinitis pigmentosa

Publications (1)

Publication Number Publication Date
MX2018002899A true MX2018002899A (es) 2018-09-12

Family

ID=54362987

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002899A MX2018002899A (es) 2015-09-10 2016-09-09 Tratamiento de retinitis pigmentosa.
MX2022003859A MX2022003859A (es) 2015-09-10 2018-03-07 Compuestos para usarse en el tratamiento o prevencion de retinitis pigmentosa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003859A MX2022003859A (es) 2015-09-10 2018-03-07 Compuestos para usarse en el tratamiento o prevencion de retinitis pigmentosa.

Country Status (14)

Country Link
US (3) US20180273594A1 (es)
EP (1) EP3347371B1 (es)
JP (1) JP7011580B2 (es)
KR (1) KR20180043373A (es)
CN (1) CN108699118A (es)
AU (2) AU2016320551C1 (es)
CA (1) CA2995656A1 (es)
GB (1) GB201516066D0 (es)
HK (1) HK1250727A1 (es)
IL (1) IL257881B (es)
MX (2) MX2018002899A (es)
RU (2) RU2020137429A (es)
SG (1) SG10202013246VA (es)
WO (1) WO2017042584A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122020011529B1 (pt) 2014-02-12 2022-11-29 Gyroscope Therapeutics Limited Aparelho para a liberação de agente terapêutico em um olho
US9925088B2 (en) 2014-06-06 2018-03-27 Janssen Biotech, Inc. Sub-retinal tangential needle catheter guide and introducer
US9949874B2 (en) 2014-06-06 2018-04-24 Janssen Biotech, Inc. Therapeutic agent delivery device with convergent lumen
US10219936B2 (en) 2014-09-11 2019-03-05 Orbit Biomedical Limited Therapeutic agent delivery device with advanceable cannula and needle
US10258502B2 (en) 2014-09-18 2019-04-16 Orbit Biomedical Limited Therapeutic agent delivery device
GB201516066D0 (en) * 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
US10478553B2 (en) 2016-03-09 2019-11-19 Orbit Biomedical Limited Apparatus for subretinal administration of therapeutic agent via a curved needle
US10646374B2 (en) 2016-06-17 2020-05-12 Orbit Biomedical Limited Apparatus and method to form entry bleb for subretinal delivery of therapeutic agent
US10806629B2 (en) 2016-06-17 2020-10-20 Gyroscope Therapeutics Limited Injection device for subretinal delivery of therapeutic agent
US11000410B2 (en) 2016-06-17 2021-05-11 Gyroscope Therapeutics Limited Guide apparatus for tangential entry into suprachoroidal space
US11273072B2 (en) 2017-01-13 2022-03-15 Gyroscope Therapeutics Limited Suprachoroidal injection device
US11076984B2 (en) 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
JOP20210054A1 (ar) * 2018-09-21 2020-03-21 Nightstarx Ltd تركيبات وطرق لعلاج التهاب الشبكية الصباغي
JP2020174859A (ja) * 2019-04-17 2020-10-29 学校法人日本医科大学 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法
GB202005641D0 (en) * 2020-04-17 2020-06-03 Ucl Business Plc Gene therapy for bardet-biedl syndrome
CN113952472A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
WO2022021149A1 (zh) * 2020-07-29 2022-02-03 北京中因科技有限公司 Aav介导的rpgr x连锁视网膜变性的基因编辑治疗
US20230338580A1 (en) * 2020-08-14 2023-10-26 Case Western Reserve University Plasmid vectors and nanoparticles for treating ocular disorders
AU2021337530B2 (en) 2020-09-02 2023-08-24 4D Molecular Therapeutics Inc. Codon Optimized RPGRorf 15 Genes And Uses Thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008801D0 (en) 2000-04-10 2000-05-31 Medical Res Council Sequences
US7799904B2 (en) * 2003-06-13 2010-09-21 University Of Kentucky Research Foundation Gilvocarcin gene cluster, recombinant production and use thereof
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
FR2949115B1 (fr) * 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
ES2362604B1 (es) 2009-12-22 2012-06-28 Bcn Peptides, S.A. Formulación tópica oftálmica de péptidos.
CN110777124A (zh) * 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
EP2872183B1 (en) 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
US9534225B2 (en) 2014-04-15 2017-01-03 Applied Genetic Technologies Corporation Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (RPGR)
GB201412011D0 (en) 2014-07-04 2014-08-20 Ucl Business Plc Treatments
HUE052781T2 (hu) 2014-07-24 2021-05-28 Massachusetts Eye & Ear Infirmary RPGR génterápia a retinitis pigmentosa terápiájára
GB201516066D0 (en) * 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa

Also Published As

Publication number Publication date
RU2020137429A (ru) 2022-01-17
GB201516066D0 (en) 2015-10-28
US20210130425A1 (en) 2021-05-06
RU2018112506A (ru) 2019-10-10
KR20180043373A (ko) 2018-04-27
US20180273594A1 (en) 2018-09-27
RU2018112506A3 (es) 2020-01-27
IL257881A (en) 2018-05-31
CN108699118A (zh) 2018-10-23
HK1250727A1 (zh) 2019-01-11
EP3347371A1 (en) 2018-07-18
WO2017042584A1 (en) 2017-03-16
IL257881B (en) 2022-12-01
AU2016320551B2 (en) 2021-11-25
SG10202013246VA (en) 2021-02-25
JP2018529336A (ja) 2018-10-11
RU2737049C2 (ru) 2020-11-24
EP3347371B1 (en) 2023-05-10
US10836803B2 (en) 2020-11-17
JP7011580B2 (ja) 2022-01-26
US20200002392A1 (en) 2020-01-02
MX2022003859A (es) 2022-06-09
AU2022200306A1 (en) 2022-02-10
CA2995656A1 (en) 2017-03-16
AU2016320551A1 (en) 2018-03-08
AU2016320551C1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
MX2022003859A (es) Compuestos para usarse en el tratamiento o prevencion de retinitis pigmentosa.
PH12016501763A1 (en) Multispecific antibodies
PH12017502255A1 (en) Nrf2 regulators
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
MX2017000569A (es) Emulsiones de silicona.
MX2017004510A (es) Triazolopirazinonas como inhibidores de pde1.
PH12019502002A1 (en) Combination theraphy
MX2017002538A (es) Absorbedor para unión de metales y la producción del mismo.
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
MX370412B (es) Compuesto antimicotico.
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
SA517380723B1 (ar) rHu-GCSF طريقة لتنقية
MX2017008280A (es) Proceso para elaborar cenicriviroc y analogos relacionados.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2016014227A (es) Estabilizante para procesos de produccion de poliol polimerico.
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
MX2020007742A (es) Procesos para preparar fluorocetolidos.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MY187959A (en) Reactor
MX2017009632A (es) Tratamiento conjunto usando conjugado anticuerpo-farmaco dirigido a (cd-19) y vincristina.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors